JP2015505315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505315A5 JP2015505315A5 JP2014551338A JP2014551338A JP2015505315A5 JP 2015505315 A5 JP2015505315 A5 JP 2015505315A5 JP 2014551338 A JP2014551338 A JP 2014551338A JP 2014551338 A JP2014551338 A JP 2014551338A JP 2015505315 A5 JP2015505315 A5 JP 2015505315A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- polypeptide
- use according
- expression
- mhc class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 65
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 27
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 27
- 230000000694 effects Effects 0.000 claims 26
- 102000043131 MHC class II family Human genes 0.000 claims 21
- 108091054438 MHC class II family Proteins 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 230000000890 antigenic effect Effects 0.000 claims 10
- 102000006386 Myelin Proteins Human genes 0.000 claims 8
- 108010083674 Myelin Proteins Proteins 0.000 claims 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000015943 Coeliac disease Diseases 0.000 claims 4
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 4
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 201000006152 substance dependence Diseases 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 2
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 108010010974 Proteolipids Proteins 0.000 claims 2
- 102000016202 Proteolipids Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 102000047918 Myelin Basic Human genes 0.000 claims 1
- 101710107068 Myelin basic protein Proteins 0.000 claims 1
- 101710126382 Signal recognition particle receptor subunit alpha Proteins 0.000 claims 1
- 102100026900 Signal recognition particle receptor subunit alpha Human genes 0.000 claims 1
- 101710111458 Signal recognition particle receptor subunit alpha homolog Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000002472 amphetamine abuse Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 108010087487 myelin basic protein 85-99 Proteins 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584045P | 2012-01-06 | 2012-01-06 | |
| US61/584,045 | 2012-01-06 | ||
| PCT/US2013/020287 WO2013103816A1 (en) | 2012-01-06 | 2013-01-04 | Partial mhc constructs and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505315A JP2015505315A (ja) | 2015-02-19 |
| JP2015505315A5 true JP2015505315A5 (enExample) | 2016-02-25 |
| JP6364352B2 JP6364352B2 (ja) | 2018-07-25 |
Family
ID=47561855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551338A Expired - Fee Related JP6364352B2 (ja) | 2012-01-06 | 2013-01-04 | 部分的ｍｈｃコンストラクト及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150044245A1 (enExample) |
| EP (1) | EP2800582A1 (enExample) |
| JP (1) | JP6364352B2 (enExample) |
| KR (1) | KR20140114859A (enExample) |
| CN (1) | CN104105503A (enExample) |
| AU (1) | AU2013207489A1 (enExample) |
| BR (1) | BR112014016652A2 (enExample) |
| CA (1) | CA2860678A1 (enExample) |
| MX (1) | MX2014008146A (enExample) |
| RU (1) | RU2014132426A (enExample) |
| WO (1) | WO2013103816A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2242393C1 (ru) * | 2003-05-12 | 2004-12-20 | Производственное республиканское унитарное предприятие "Минский автомобильный завод" | Механизм опрокидывания кабины |
| US8685404B2 (en) * | 2011-01-31 | 2014-04-01 | Oregon Health & Science University | Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction |
| EP3052138A4 (en) * | 2013-10-03 | 2017-04-12 | Oregon Health & Science University | Treatment of ischemic stroke with dr 1-mog-35-55 |
| EP3052526A4 (en) * | 2013-10-03 | 2017-04-19 | Oregon Health & Science University | Recombinant polypeptides comprising mhc class ii 1 domains |
| WO2017070569A1 (en) | 2015-10-23 | 2017-04-27 | Oregon Health & Science University | Compounds that bind macrophage migration inhibitory factor |
| US20170196957A1 (en) | 2016-01-08 | 2017-07-13 | Oregon Health & Science University | Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer |
| WO2018006067A1 (en) * | 2016-07-01 | 2018-01-04 | Loma Linda University | Myelin oligodendrocyte glycoprotein-specific peptide for the treatment or prevention of multiple sclerosis |
| WO2020037046A1 (en) * | 2018-08-14 | 2020-02-20 | Board Of Regents, The University Of Texas System | Single molecule sequencing peptides bound to the major histocompatibility complex |
| EP3860644A1 (en) * | 2018-10-05 | 2021-08-11 | Oregon Health & Science University | Recombinant polypeptides comprising modified mhc class ii dra1 domains and methods of use |
| KR20220110233A (ko) * | 2019-12-02 | 2022-08-05 | 리제너론 파마슈티칼스 인코포레이티드 | 펩티드-mhc ii 단백질 작제물 및 그의 용도 |
| DE102020109447A1 (de) * | 2020-04-03 | 2021-10-07 | Jacobs University Bremen Ggmbh | Synthetisches mhc-klasse-ii-protein |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468481A (en) | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| JP3603374B2 (ja) * | 1995-04-14 | 2004-12-22 | 東レ株式会社 | 融合蛋白質およびその融合蛋白質を固定化した材料 |
| ES2221065T3 (es) * | 1996-08-16 | 2004-12-16 | The President And Fellows Of Harvard College | Proteinas de fusion de clase ii del mhc, solubles, monovalentes o polivalentes, y sus usos. |
| US20030007978A1 (en) | 1997-09-16 | 2003-01-09 | Burrows Gregory G. | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| EP1017721B1 (en) | 1997-09-16 | 2009-02-25 | Oregon Health and Science University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| US6232445B1 (en) * | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
| WO1999042597A1 (en) * | 1998-02-19 | 1999-08-26 | President And Fellows Of Harvard College | Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor |
| WO2005044982A2 (en) * | 2003-09-05 | 2005-05-19 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| US7576183B2 (en) * | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| JP2008537736A (ja) | 2005-03-18 | 2008-09-25 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子 |
| US20110008382A1 (en) | 2009-03-07 | 2011-01-13 | Burrows Gregory G | Compositions and methods using recombinant MHC molecules for the treatment of uveitis |
| US8491913B2 (en) | 2009-03-07 | 2013-07-23 | Oregon Health & Science University | Compositions and methods using recombinant MHC molecules for the treatment of stroke |
-
2013
- 2013-01-04 BR BR112014016652A patent/BR112014016652A2/pt not_active IP Right Cessation
- 2013-01-04 WO PCT/US2013/020287 patent/WO2013103816A1/en not_active Ceased
- 2013-01-04 CA CA2860678A patent/CA2860678A1/en not_active Abandoned
- 2013-01-04 RU RU2014132426A patent/RU2014132426A/ru not_active Application Discontinuation
- 2013-01-04 CN CN201380004958.1A patent/CN104105503A/zh active Pending
- 2013-01-04 US US14/370,454 patent/US20150044245A1/en not_active Abandoned
- 2013-01-04 JP JP2014551338A patent/JP6364352B2/ja not_active Expired - Fee Related
- 2013-01-04 KR KR1020147021913A patent/KR20140114859A/ko not_active Withdrawn
- 2013-01-04 MX MX2014008146A patent/MX2014008146A/es unknown
- 2013-01-04 AU AU2013207489A patent/AU2013207489A1/en not_active Abandoned
- 2013-01-04 EP EP13700425.5A patent/EP2800582A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505315A5 (enExample) | ||
| RU2014132426A (ru) | Частичные конструкты мнс и способы их применения | |
| Kukreja et al. | Autoimmunity and diabetes | |
| US10485882B2 (en) | Nanoparticle compositions for sustained therapy | |
| JP2012525844A5 (enExample) | ||
| Leibowitz et al. | Immune mechanisms in hypertension | |
| Johnson | Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis | |
| WO2019104245A1 (en) | Use and production of engineered immune cells | |
| KR20220137009A (ko) | 염증 질환을 치료하기 위한 방법 및 약제학적 조성물 | |
| CN104136457A (zh) | 包括白细胞介素10和白细胞介素4的融合蛋白 | |
| JP2014523871A5 (enExample) | ||
| US20240052006A1 (en) | Anti-inflammatory cytokines and methods of use | |
| EP3716949A1 (en) | Methods of treating autoimmune disease | |
| Leadbetter et al. | Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide | |
| JP2024517474A (ja) | Ｈｌａ操作の方法及び自己免疫の治療方法 | |
| Boppana et al. | Immunologic aspects of multiple sclerosis | |
| Consonni et al. | a novel approach to reinstating Tolerance in experimental autoimmune Myasthenia gravis Using a Targeted Fusion Protein, mcTa1–T146 | |
| CN115667309A (zh) | 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 | |
| US11098296B2 (en) | Mutants of cocaine esterase | |
| CN110139659B (zh) | 用于治疗干燥综合征的肽 | |
| Garren | A DNA vaccine for multiple sclerosis | |
| L. Evans-Marin et al. | Gut homing molecule regulation of the pathogenesis and treatment of inflammatory bowel diseases | |
| Nalawade et al. | Advances in Understanding the Role of MIF in the Pathogenesis of Autoimmune Diseases | |
| Hughes et al. | Fingolimod (FTY720) oral for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 FORCIDP trial | |
| WO2025133131A1 (en) | Bispecific conjugate for antigen-specific b cell depletion by t cells |